Across TCGA pan-cancer cohorts, NAT8L mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of NAT8L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where NAT8L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types NAT8L is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

CCRCC are the cancer types where NAT8L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NAT8L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	−1.312	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: NAT8L RNA expression & survival · all NAT8L data types